0000000000394078

AUTHOR

Enrique De ÁLava

0000-0001-8400-046x

showing 5 related works from this author

(Immuno)histological Analysis of Ewing Sarcoma

2020

The diagnosis of Ewing sarcoma requires the integration of the information generated from numerous techniques, some of them being very sophisticated. However, the first steps of the diagnostic process are crucial to achieve the maximum possible diagnostic performance. In this chapter we will review how to handle the diagnostic specimen from its collection, how to prepare it for diagnosis, how to make a complete pathology report, and provide guidance for the reasonable use of immunohistochemical techniques in this malignancy.

0301 basic medicinePathologymedicine.medical_specialtyBone decalcificationbusiness.industrymedicine.medical_treatmentPathology Reportmedicine.diseaseMalignancy03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesismedicineImmunohistochemistrySarcomaDifferential diagnosisbusinessNeoadjuvant therapy
researchProduct

Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma

2021

Ewing sarcoma (EWS) is an aggressive bone and soft tissue tumor of children and young adults in which the principal driver is a fusion gene, EWSR1-FLI1. Although the essential role of EWSR1-FLI1 protein in the regulation of oncogenesis, survival, and tumor progression processes has been described in-depth, little is known about the regulation of chimeric fusion-gene expression. Here, we demonstrate that the active nuclear HDAC6 in EWS modulates the acetylation status of specificity protein 1 (SP1), consequently regulating the SP1/P300 activator complex binding to EWSR1 and EWSR1-FLI1 promoters. Selective inhibition of HDAC6 impairs binding of the activator complex SP1/P300, thereby inducing…

Cancer ResearchCarcinogenesisSarcoma EwingBiologymedicine.disease_causeHistone Deacetylase 6ArticleFusion genePaediatric cancerDownregulation and upregulationGeneticsmedicineHumansDoxorubicinPromoter Regions GeneticMolecular BiologyActivator (genetics)Proto-Oncogene Protein c-fli-1AcetylationOncogenesmedicine.diseaseTumor progressionFLI1Cancer researchSarcomaCarcinogenesismedicine.drug
researchProduct

Molecular diagnosis of dermatofibrosarcoma protuberans: A comparison between reverse transcriptase-polymerase chain reaction and fluorescence in situ…

2011

Dermatofibrosarcoma protuberans (DFSP) is characterized by the presence of the t(17;22)(q22;q13) that leads to the fusion of the COL1A1 and PDGFB genes. This translocation can be detected by multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) or fluorescence in situ hybridization (FISH) techniques. We have evaluated the usefulness of a dual color dual fusion FISH probe strategy for COL1A1/PDGFB detection in a series of 103 archival DFSPs and compared the obtained results with RT-PCR analyses. FISH and RT-PCR were carried out on paraffin embedded tissue samples. Regarding the RT-PCR approach, all COL1A1 exons and exon 2 of PDGFB were evaluated. Sensitivity, specificity, positi…

AdultMaleCancer ResearchCD34Chromosomal translocationBiologyCollagen Type Ilaw.inventionlawGeneticsmedicineDermatofibrosarcoma protuberansHumansChildIn Situ Hybridization FluorescencePolymerase chain reactionFibrosarcomatous Dermatofibrosarcoma ProtuberansPDGFBmedicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionDermatofibrosarcomaProto-Oncogene Proteins c-sismedicine.diseaseMolecular biologyCollagen Type I alpha 1 ChainImmunohistochemistryFluorescence in situ hybridizationGenes Chromosomes and Cancer
researchProduct

The first European interdisciplinary ewing sarcoma research summit.

2012

This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License.-- et al.

EpigenomicsCancer ResearchAlternative medicineMedizinComputingMilieux_LEGALASPECTSOFCOMPUTINGReview ArticleBioinformatics[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologydrug screen0302 clinical medicineDrug screenCancer genomicssignallingSarcomagenesis0303 health sciencessarcomagenesisSummitgeography.geographical_feature_categoryOpinion leadershipGenomicsLaboratory resultslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisanimal models3. Good healthAnimal modelsMetastatic Ewing SarcomaOncology030220 oncology & carcinogenesis[SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]EpigeneticsSarcomaImmunotherapyPrioritizationmedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/Cancerlcsh:RC254-28203 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/Cancer[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]medicinegenomics030304 developmental biologyMedical educationgeographyepigeneticsbusiness.industrybiomarkers[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologymedicine.diseaseClinical trialprognosisbusinessBiomarkersEwing sarcomaFrontiers in oncology
researchProduct

Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial

2020

[Background] Solitary fibrous tumour is an ultra-rare sarcoma, which encompasses different clinicopathological subgroups. The dedifferentiated subgroup shows an aggressive course with resistance to pazopanib, whereas in the malignant subgroup, pazopanib shows higher activity than in previous studies with chemotherapy. We designed a trial to test pazopanib activity in two different cohorts of solitary fibrous tumour: the malignant-dedifferentiated cohort, which was previously published, and the typical cohort, which is presented here.

0301 basic medicineMalemedicine.medical_specialtyIndazolesPazopanib03 medical and health sciences0302 clinical medicineInternal medicinemedicineClinical endpointHumansProspective StudiesNeoplasm MetastasisProspective cohort studySurvival rateProtein Kinase InhibitorsResponse Evaluation Criteria in Solid TumorsAgedSulfonamidesPerformance statusbusiness.industryMiddle Agedmedicine.diseasePrognosisClinical trialSurvival Rate030104 developmental biologyPyrimidinesOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisSolitary Fibrous TumorsFemalebusinessProgressive diseasemedicine.drugFollow-Up Studies
researchProduct